Tiragolumab with atezolizumab for treating stage III non-small cell lung cancer after platinum-based chemoradiotherapy

Tiragolumab with atezolizumab is currently in development for locally advanced, unresectable stage III non-small cell lung cancer (NSCLC) in patients who have received at least two cycles of chemoradiotherapy. Stage III NSCLC describes a locally advanced disease state where the cancer has spread beyond the lung that was initially affected, such as surrounding lymph nodes, the heart, spinal bones and windpipe. Most patients with NSCLC are diagnosed at the advanced/metastatic stage where curative treatment with surgery is unsuitable. Therefore chemotherapy/radiotherapy along with systemic anti-cancer treatments are given to patients to improve long-term survival outcomes.